What question did this study set out to answer?

To evaluate whether an adapted whole-blood impedance aggregometer can reliably assess platelet function and GP IIb/IIIa receptor blockade at the bedside in coronary angioplasty patients.

December 2, 1997Circulation

Rapid Assessment of Platelet Function With a Modified Whole-Blood Aggregometer in Percutaneous Transluminal Coronary Angioplasty Patients Receiving Anti-GP IIb/IIIa Therapy

View Full Paper

Ask AI

Bookmark

Why the study?

Does a modified whole-blood aggregometer accurately measure pharmacological GP IIb/IIIa blockade compared to turbidimetric aggregation in PTCA patients receiving abciximab?

Population

14 percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy

Comparison

Platelet function assessment using a modified… vs Turbidimetric aggregation and GP IIb/IIIa…

Design

Cohort

Follow-up

36 hours after abciximab treatment

Authors

MMMary Ann MascelliChinook Regional Hospital SWSeth J. WorleyElectrophysiology NVNicholas J. VeriaboLancaster General Hospital

Discussion

Member takes

Implication

May support bedside impedance aggregometry for abciximab monitoring in PTCA; leaves open prospective validation against outcomes.

Key Points

To evaluate whether an adapted whole-blood impedance aggregometer can reliably assess platelet function and GP IIb/IIIa receptor blockade at the bedside in coronary angioplasty patients.
Evaluated 14 high-risk percutaneous transluminal coronary angioplasty (PTCA) patients receiving a standard bolus plus a 12-hour infusion of abciximab.
Measured GP IIb/IIIa receptor blockade, electrical impedance aggregation (5 µg/mL collagen), and turbidimetric aggregation (5 and 20 µmol/L ADP) during infusion, at 12 hours post-infusion, and at 36 hours post-infusion (n=8).
During abciximab administration, mean GP IIb/IIIa receptor blockade exceeded 91%, with both impedance and turbidimetric aggregation inhibited by ≥90%.
At 12 hours post-treatment, inhibition of impedance aggregation was 69±12%, turbidimetric aggregation inhibition was 65±20% (5 µmol/L ADP) and 49±14% (20 µmol/L ADP), and receptor blockade was 67±8%.
At 36 hours post-treatment (n=8), impedance aggregation inhibition remained at 60±14% and closely paralleled receptor blockade (57±7%), whereas turbidimetric inhibition dropped to 44±21% (5 µmol/L ADP) and 30±14% (20 µmol/L ADP).

Structured PICO

Does a modified whole-blood aggregometer accurately measure pharmacological GP IIb/IIIa blockade compared to turbidimetric aggregation in PTCA patients receiving abciximab?

Population

14 percutaneous transluminal coronary angioplasty (PTCA) patients receiving anti-GP IIb/IIIa therapy (abciximab)

Intervention

Platelet function assessment using a modified whole-blood aggregometer (Chrono-log Whole Blood Aggregometer) measuring electrical impedance

Comparator

Turbidimetric aggregation (5 and 20 micromol/L ADP) and GP IIb/IIIa receptor blockade measurements

Outcome

Correlation of impedance aggregation with GP IIb/IIIa receptor blockade and turbidimetric aggregation during and up to 36 hours after abciximab therapysurrogate

Whole-blood impedance aggregometry provides a reliable point-of-care method to monitor GP IIb/IIIa receptor blockade during and after abciximab therapy in PTCA patients.

Cite This Study

Mascelli et al. (1997) studied this question.

synapsesocial.com/papers/6a75591d01b447f0dadc16bc https://doi.org/10.1161/01.cir.96.11.3860

View Full Paper

Ask AI

Bookmark

Rapid Assessment of Platelet Function With a Modified Whole-Blood Aggregometer in Percutaneous Transluminal Coronary Angioplasty Patients Receiving Anti-GP IIb/IIIa Therapy

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Rapid Assessment of Platelet Function With a Modified Whole-Blood Aggregometer in Percutaneous Transluminal Coronary Angioplasty Patients Receiving Anti-GP IIb/IIIa Therapy

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider